ARCS-M: forging progress from this negative trial in malignant pleural mesothelioma. Zauderer MG, Offin M. Lancet Oncol 2022;23:445-446.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zauderer MG, Offin M. ARCS-M: forging progress from this negative trial in malignant pleural mesothelioma. Lancet Oncol 2022;23:445-446.
PMID: 35358447